ASCO has measures that have been fully developed and are not yet NQF-endorsed or implemented in a program. ASCO measures are copyrighted, and commercial uses of the measures require a license agreement between the user and ASCO. Commercial use is defined as the sale, license, or distribution of the measures for commercial gain, or incorporation of the measure into a product or service that is sold, licensed, or distributed for commercial gain. If your organization is interested in licensing ASCO measures, please contact measurement@asco.org.
|
Measure Title |
Year Developed |
|
Appropriate Antiemetic Therapy for Moderate-Emetic-Risk Antineoplastic Agents |
2019 |
|
Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents – Avoidance of Overuse (Lower Score – Better) |
2019 |
|
Moderate Hypofractionation for Prostate Cancer |
2019 |
|
Hypofractionated Whole Breast Irradiation |
2019 |
|
BRAF Molecular Screening During Workup for Advanced Melanoma |
2019 |
|
Screening for Brain Metastases at Initial Diagnosis of Advanced Melanoma |
2019 |